Sequenom Shares Skyrocket More Than 37 Percent on Cancer Study Findings | GenomeWeb

NEW YORK, Dec. 15 (GenomeWeb News) - Shares in Sequenom were up 37.84 percent at $1.53 in late-afternoon trading after the company said its flagship technology helped discover gene variants linked to a 40-percent increased risk of developing breast and prostate cancer.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.